| The role of enzymology in a structure-based drug discovery program: bacterial DNA gyrase. | |
| | |
MedLine Citation:
|
PMID: 22222453 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The capability to accurately, rapidly, and reproducibly determine the affinity of a ligand for a target protein or enzyme is a vital component for a successful structure-based drug design effort. In order to successfully drive a structure-based drug design (SBDD) project forward, multiple distinct assays, each with particular strengths and weaknesses, need to be employed. Using bacterial DNA gyrase as an example, a range of assays are described that will fully support an SBDD program. |
| | |
Authors:
|
Mark L Cunningham |
Related Documents
:
|
15985813 - Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy? 22165263 - Global: commission on drug policy declares drug war a failure, urges reforms. 12030213 - Special coverage: 9th conference on retroviruses. new drugs, new data hold promise for ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Methods in molecular biology (Clifton, N.J.) Volume: 841 ISSN: 1940-6029 ISO Abbreviation: Methods Mol. Biol. Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-01-06 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9214969 Medline TA: Methods Mol Biol Country: United States |
Other Details:
|
Languages: eng Pagination: 179-207 Citation Subset: IM |
Affiliation:
|
Trius Therapeutics, San Diego, CA, USA, mcunningham@triusrx.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Crystallographic fragment screening.
Next Document: Leveraging structural information for the discovery of new drugs: computational methods.